Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome
- PMID: 17487763
- DOI: 10.1080/14017430601164263
Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome
Abstract
Objectives: To investigate the association between inflammatory mediators, matrix degrading enzymes and acute coronary syndrome (ACS) and the impact of early reperfusion therapy on circulating biomarkers.
Design: Peripheral serum levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were determined in 134 patients with ACS. These biomarkers were serially monitored in ten patients with intravenous thrombolytic therapy (IVT).
Results: Serum levels of IL-6, hs-CRP and MMP-9 were higher in unstable angina (UA) and myocardial infarction (MI) groups than in control or SA group (p<0.05). Peripheral IL-6 level in patients with MI was greater after percutaneous coronary intervention (PCI) (p<0.01) or IVT (p<0.05). Serial concentration determination revealed marked elevation of serum IL-6 and MMP-9 levels, both reaching peak values (like creatine kinase-MB).
Conclusions: Elevated levels of IL-6, hs-CRP and MMP-9 provide a link between inflammation, matrix degradation and the development and progression of ACS. IL-6 and MMP-9 appear to be released mainly from vulnerable plaque or necrotic myocardium during the acute phase of MI.
Similar articles
-
In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.J Cardiovasc Med (Hagerstown). 2007 Aug;8(8):602-7. doi: 10.2459/JCM.0b013e32802e6c28. J Cardiovasc Med (Hagerstown). 2007. PMID: 17667031
-
Soluble CD40 ligand and interleukin-6 in the coronary circulation after acute myocardial infarction.Int J Cardiol. 2006 Sep 10;112(1):52-8. doi: 10.1016/j.ijcard.2005.09.051. Epub 2006 Jan 10. Int J Cardiol. 2006. PMID: 16376442
-
Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease.Intern Med J. 2005 Jun;35(6):331-5. doi: 10.1111/j.1445-5994.2005.00822.x. Intern Med J. 2005. PMID: 15892761
-
[Diagnostic and prognostic significance of CK-MB, troponins, CRP, BNP and/or NT-proBNP in coronary angioplasty. Elevation mechanisms and clinical implications].Arch Mal Coeur Vaiss. 2007 Nov;100(11):925-33. Arch Mal Coeur Vaiss. 2007. PMID: 18209693 Review. French.
-
Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability.Mt Sinai J Med. 2006 Jan;73(1):431-9. Mt Sinai J Med. 2006. PMID: 16470323 Review.
Cited by
-
Postconditioning with α7nAChR agonist attenuates systemic inflammatory response to myocardial ischemia--reperfusion injury in rats.Inflammation. 2012 Aug;35(4):1357-64. doi: 10.1007/s10753-012-9449-2. Inflammation. 2012. PMID: 22391744
-
Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway.Drug Des Devel Ther. 2015 Jun 23;9:3217-29. doi: 10.2147/DDDT.S86431. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26150695 Free PMC article.
-
Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial.Circ Cardiovasc Interv. 2020 Apr;13(4):e008717. doi: 10.1161/CIRCINTERVENTIONS.119.008717. Epub 2020 Apr 16. Circ Cardiovasc Interv. 2020. PMID: 32295417 Free PMC article. Clinical Trial.
-
Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases.Front Pharmacol. 2021 Aug 24;12:745061. doi: 10.3389/fphar.2021.745061. eCollection 2021. Front Pharmacol. 2021. PMID: 34504432 Free PMC article. Review.
-
Correlations between serum inflammation factors and left ventricular remodeling in acute ST segment elevation myocardial infarction.Yonsei Med J. 2012 May;53(3):501-7. doi: 10.3349/ymj.2012.53.3.501. Yonsei Med J. 2012. PMID: 22476992 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous